Kokichi Suzuki

发表

Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor.

F. Gonzalez, K. Yoshinari, M. Shimada, 2009, Biological & pharmaceutical bulletin.

Enhancement of Fibrinolysis by EF6265 [(S)-7-Amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic Acid], a Specific Inhibitor of Plasma Carboxypeptidase B

M. Nomoto, C. Kikuchi, H. Ishii, 2004, Journal of Pharmacology and Experimental Therapeutics.

Structural Requirements for Alkylglycoside-Type Renal Targeting Vector

Y. Sugiyama, S. Nakabayashi, H. Susaki, 1999, Pharmaceutical Research.

Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.

Ken Kitahara, T. Ninomiya, A. Sugiyama, 2014, Toxicology and applied pharmacology.

EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats*

H. Ishii, H. Iida, Y. Muto, 2009, Critical care medicine.

EF6265, a Novel Plasma Carboxypeptidase B Inhibitor, Protects against Renal Dysfunction in Rat Thrombotic Glomerulonephritis through Enhancing Fibrinolysis

H. Ishii, H. Iida, Y. Muto, 2007, Nephron Experimental Nephrology.

Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats.

H. Ishii, Eriko Sato, Y. Muto, 2003, European journal of pharmacology.

Delivery of Drugs and Antisense Oligonucleotides to the Proximal Tubular Cell of the Kidney Using Macromolecular and Pro‐drug Approaches

Y. Sugiyama, D. Meijer, Y. Kato, 2001 .

EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats*

H. Ishii, H. Iida, Y. Muto, 2009, Critical care medicine.